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Abstract 
Objectives: The irinotecan (CPT-11) + 5-fluorouracil (5-FU)/leucovorin (LV) + UFT/LV 
chemotherapy, in which repetitive oral administration of UFT/LV replaces the infusion 
of 5-FU/LV in the FOLFIRI regimen, has been proposed previously. In this study, five of 
10 patients were injected with a bolus of 5-FU and the other were not injected with it in 
order to examine the effect of omitting it in terms of pharmacokinetics of 5-FU. 
Methods: The treatment consisted of the intravenous infusions of CPT-11 at 100 mg/m2 
and l-LV at 15 mg/m2, and the injection of a bolus of 5-FU at 500 mg/m2 on day 1, and 
the repetitive oral administration of UFT/LV (300 mg/m2/day as tegafur + 75 mg/day of 
LV) on days 1-5. A total of 13 measurements of the plasma concentrations of uracil, 5-FU 
and tegafur were made per patient within 48 hr after the start of chemotherapy and the 
value of area under the concentration-time curve (AUC0-48) was evaluated. The plasma 
concentration was also determined at 2 weeks to assess long-term exposure to 5-FU. 
Results: The plasma concentrations of 5-FU at 24 hr after the start of treatment were 27.4 
ng/mL and 9.4 ng/mL in the patients with and without the bolus injection, respectively. 
At 48 hr, they were 31.3 ng/mL and 10.4 ng/mL with the AUC0-48 values of 22.16 mg*h/L 
and 0.65 mg*h/L, respectively. The 5-FU was detected in the plasma at 226 hr after the 
last administration of UFT/LV for the patients with the bolus injection, but not for those 
without.  
Conclusion: A bolus of 5-FU on day 1 provided long-term exposure to 5-FU. 
Key words: 5-fluorouracil, UFT, bolus injection, constant infusion, pharmacokinetics 
Introduction 
The treatment of metastatic colorectal cancer has 
progressed  significantly  after  developments  of  iri-
notecan (CPT-11) and oxaliplatin (L-OHP). Currently, 
the FOLFIRI or FOLFOX regimen with or without a 
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targeted monoclonal antibody, is the standard treat-
ment [1-4], and future improvements will likely re-
quire the incorporation of or substitution with a novel 
anticancer  drug,  personalization  based  on  genetic 
profiling, or pharmacokinetically-guided administra-
tion.  
 The oral fluoropyrimidine UFT and capecitabine 
have been developed to improve tolerability and pa-
tient convenience, and have replaced continuous in-
fusion of 5-FU in many treatment regimens [5]. UFT is 
a combination of tegafur, an oral prodrug of 5-FU, and 
uracil  in  a  molar  ratio  of  1:  4.  Tegafur  produces  a 
constant  reserve  of  5-FU  and  its  active  metabolites, 
and  provides  pharmacokinetics  equivalent  to  the 
constant  infusion  of  5-FU.  Uracil  is  an  endogenous 
substrate for dihydropyrimidine dehydrogenase, the 
main enzyme responsible for the degradation of 5-FU, 
and enhances the anticancer effects of 5-FU. In reports 
published in 2002, UFT with LV proved comparable 
with  bolus  5-FU/LV-based  regimens  in  two  multi-
center, randomized phase III trials [6,7]. Subsequent-
ly, a number of phase II clinical trials have demon-
strated the efficacy and tolerability of UFT in combi-
nation with CPT-11 or L-OHP in the first-line treat-
ment of metastatic colorectal cancer [8-14]. The novel 
regimens  have  been  referred  to  as  TEGAFIRI  and 
TEGAFOX, respectively.  
 Previously, the phase I study on the CPT-11 + 
5-FU/LV + UFT/LV chemotherapy, in which repeti-
tive oral administration of UFT/LV (300 mg/m2/day 
as tegafur + 75 mg/day of LV) replaces the infusion of 
5-FU/LV (2,400 mg/m2/46h of 5-FU + 400 mg/m2/2h 
of LV) in the FOLFIRI regimen, has been conducted in 
the patients with advanced colorectal cancer [15]. The 
FOLFIRI regimen consists of a bolus injection of 5-FU, 
CPT-11 and infusion of 5-FU/LV, and recently critical 
evaluations have been performed with regard to the 
necessity  of  a  bolus  injection  of  5-FU  [1-4].  In  this 
study, the effect of a bolus of 5-FU on its steady-state 
pharmacokinetics  was  examined  in  the  CPT-11  + 
5-FU/LV + UFT/LV chemotherapy. 
Patients and Methods 
Eligibility 
 Ten patients were enrolled from September 2004 
to May 2006 in this pharmacokinetic study. All pa-
tients  had  histologically  or  cytologically  confirmed 
advanced  or  metastatic  colorectal  adenocarcinoma. 
Patients had received no prior chemotherapy or only 
one  regimen  of  previous  chemotherapy  (with  a 
washout period of more than 4 weeks after the final 
day  of  the  previous  treatment).  Adjuvant  chemo-
therapy  performed  more  than  6  months  previously 
was not counted as previous treatment. Further eligi-
bility criteria included: 1) age of 20-75 years; 2) East-
ern  Cooperative  Oncology  Group  (ECOG)  perfor-
mance status of 0 or 1; 3) life expectancy of 3 months 
or more; 4) adequate hematological (absolute leuko-
cyte count: 4,000/mm3-12,000/mm3, neutrophil count: 
2,000/mm3 or more, platelets: 100,000/mm3 or more), 
hepatic (transaminases: 2.5 times or less of the upper 
limit of normal, serum bilirubin: 2.0 mg/dL or less) 
and renal (serum creatinine: less than the upper limit 
of normal) function; and 5) ability to take oral medi-
cation. Patients were excluded, if they had either brain 
metastases, a history of other neoplasms (except cured 
nonmelanoma skin carcinoma or cured carcinoma in 
situ),  a  history  of  severe  drug  allergy,  interstitial 
pneumonitis  or  pulmonary  fibrosis,  severe  pleural 
effusion or ascites, active infection, bowel obstruction, 
diarrhea,  and  serious  uncontrolled  comorbidity  or 
medical conditions. Pregnant or lactating women or 
women not using an effective contraception were also 
excluded. This study was conducted at Kobe Univer-
sity Hospital, Japan. The institutional review board of 
the institute reviewed and approved the protocol be-
fore commencement of the study. Written informed 
consent was obtained from all patients in advance.  
CPT-11 + 5-FU/LV + UFT/LV chemotherapy 
 The  protocol  is  presented  in  Figure  1.  The 
treatment  consisted  of  the  intravenous  infusion  of 
CPT-11 at 100 mg/m2 for 90 min, the subsequent in-
fusion of l-LV at 15 mg/m2 for 30 min, and the injec-
tion  of  a  bolus  of  5-FU  at  500  mg/m2  immediately 
after completion of the l-LV infusion on day 1, and the 
repetitive  oral  administration  of  UFT/LV  (300 
mg/m2/day as tegafur + 75 mg/day of LV) on days 
1-5. Five of 10 patients were not injected with a bolus 
of 5-FU, resulting in the reduction of dose (equivalent 
to  5-FU)  from  1474.8  mg/  m2  to  974.8  mg/m2.  The 
daily dosage of UFT/LV was divided into 3 doses and 
administered at either 1 hr before or 1 hr after food 
intake. The first dose of UFT/LV was given at 9:00 on 
day 1, 30 min before the infusion of CPT-11, and the 
second  and  third  doses  were  administered  at  17:00 
and  23:00,  respectively.  It  is  noted  that  previously 
conducted phase I study resulted in the recommen-
dation of 7 days treatment for repetitive oral admin-
istration  of  UFT/LV  and  a  dose  of  150  mg/m2  for 
CPT-11 [15]. 
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Figure 1. Protocol of the CPT-11 + 5-FU/LV + UFT/LV chemotherapy. The treatment consisted of the intravenous 
infusion of CPT-11 at 100 mg/m
2 for 90 min, the subsequent infusion of l-LV at 15 mg/m
2 for 30 min, and the injection 
of a bolus of 5-FU at 500 mg/m
2 immediately after completion of the l-LV infusion on day 1, and the repetitive oral 
administration of UFT/LV (300 mg/m
2/day as tegafur + 75 mg/day of LV) on days 1-5. The daily dosage of UFT/LV was 
divided into 3 doses and administered at either 1 hr before or 1 hr after food intake. 
 
Determination of Plasma Concentration of 5-FU 
Aliquots of blood (5 mL) were collected into et-
ylenediaminetetraacetic  acid-treated  tubes  at  9:00 
(prior to the 1st oral UFT/LV), 9:30, 10:00, 11:00, 11:30, 
11:45, 12:00, 12:30, 13:00, 17:00 (prior to the 2nd oral 
UFT/LV) and 19:00 on day 1, at 9:00 on days 2, 3 and 
15. The last sampling point was 226 hr after the final 
administration  of  UFT/LV.  The  plasma  concentra-
tions of uracil, 5-FU and tegafur were determined by 
high-performance  liquid  chromatography  (HPLC), 
under conditions modified from the report by Chu et 
al [16]. To 100 μL of plasma were added 200 μL of 
internal  standard  solution,  1.0  μg/mL  of 
5-bromouracil  in  50  mM  phosphate  buffer  (pH  2.5) 
and 750 μL of ethylacetate, and the mixture was cen-
trifuged  at  3,000  rpm  for  10  sec.  The  extraction  by 
ethylacetate  was  repeated  3  times,  and  the 
ethylacetate layers collected were evaporated under a 
stream of nitrogen gas. The residue was solved in 200 
μL of 50 mM phosphate buffer (pH 2.5), and injected 
into a HPLC system after filtration through a 0.45-μm 
membrane  filter  (Millipore  Corp.,  MA,  USA).  The 
HPLC  system  (LC-20AT,  Shimadzu  Corp.,  Kyoto, 
Japan) was equipped with a variable-wavelength UV 
detector  (SPD-20A,  Shimadzu),  adjusted  to  260  nm, 
and  an  analytic  C18  reverse-phase  column 
(CHEMCOSORB 5-ODS-H, 4.6 mm x 25 cm, Chemco 
Scientific Co., Ltd., Osaka, Japan). The mobile phases 
were  10  mM  phosphate  buffer  (pH  2.5)  (A)  and 
methanol (B), and the  gradient program  was set as 
follows: A: B = 100%: 0% at 0 min, 99%: 1% at 7 min, 
90%: 10% at 20 min, 90%: 10% at 28 min, 100%: 0% at 
29 min and 100%: 0% at 40 min. The calibration lines 
were constructed for each assay using standard solu-
tions  and  based  on  the  peak  height  ratio  to 
5-bromouracil. The calibration lines were satisfactory 
for exterminating the concentrations, with minimum 
within day or day-to-day variations. The 5-FU con-
centrations  were  validated  by  another  method  pre-
sented in other papers, and it was confirmed that this 
method provided the same values with high accuracy 
and precision [17-19]. 
Data Analysis and Statistics 
All values reported are the mean±standard de-
viation  (SD).  Area  under  the  plasma  concentra-
tion-time curve (AUC) was calculated using the linear 
trapezoidal  rule.  The  unpaired  Student’s 
t-test/Welch’s  test  or  Mann-Whitney’s  U  test  was 
used for two-group comparisons of the concentrations 
or AUC values. P values of less than 0.05 were con-
sidered to be significant.  
Results 
Table 1 lists the concentrations of 5-FU in plasma 
of patients with advanced colorectal cancer, who were 
treated with the CPT-11 + 5-FU/LV + UFT/LV regi-
men. “Time 0” means 9:00 on day 1, the time of the 
first oral administration of UFT/LV. The intravenous 
infusion of CPT-11 at 100 mg/m2 was administered 
from Time = 0.5 hr to 2 hr, and followed by the infu-
sion  of  l-LV  at  15  mg/m2  for  30  min.  Immediately 
after, a bolus of 5-FU was injected at a dose of 500 
mg/m2 in  5  of  10  patients  (with  bolus  injection  of 
5-FU),  the  other  5  was  not  injected  (without  bolus 
injection of 5-FU). In the patients with bolus injection 
of 5-FU, the plasma concentration of 5-FU increased to 
37.0±48.9 ng/mL at 1 hr after the oral administration 
of  UFT/LV,  then  rapidly  increased  to  more  than 
80,000 ng/mL on the injection of 5-FU, before drop-
ping to 25.5±10.9 ng/mL 5.5 hr later. The trough levels 
of 5-FU were 27.4±12.0 ng/mL and 31.3±11.5 ng/mL 
prior to the 4th and 7th oral administration of UFT/LV, Int. J. Med. Sci. 2011, 8 
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respectively, and 5-FU was detected at a concentration 
of 15.8±11.9 ng/mL at 336 hr after the start of treat-
ment, that is, at 226 hr after the last administration of 
UFT/LV. On the other hand, in the patients without 
bolus injection of 5-FU, the trough levels of 5-FU were 
9.4±8.0 ng/mL and 10.4±8.4 ng/mL prior to the 4th 
and 7th oral administration of UFT/LV, respectively, 
and 5-FU was not detected at 336 hr after the start of 
treatment, and these values were significantly lower 
than those with bolus injection of 5-FU. 
Table 2 lists the plasma concentrations of uracil. 
The  concentration  of  endogenous  uracil  in  plasma 
was 0-48.5 ng/mL, and increased after the oral  ad-
ministration  of  UFT/LV.  Due  to  extensive  in-
ter-individual variation of the concentrations, the ef-
fect of bolus injection of 5-FU was not clarified in this 
study.  The  data  of  tegafur  is  in  Table  3.  With  or 
without bolus injection of 5-FU, the plasma concen-
tration  of  tegafur  was  2,000-10,000  ng/mL  after  re-
petitive  oral  administration  of  UFT/LV,  and  there 
was no statistical significance between 2 groups. 
AUC0-48 values are listed in Table 4. The AUC0-48 
values  of  uracil,  5-FU  and  tegafur  were  8.50±3.68 
mg*h/L,  22.16±6.57  mg*h/L  and  227.83±50.91 
mg*h/L, respectively, in the patients treated with the 
CPT-11 + 5-FU/LV + UFT/LV regimen. Omission of 
bolus  injection  of  5-FU  did  not  affect  the  systemic 
exposure to uracil and tegafur, but AUC0-48 values of 
5-FU decreased to 0.65±0.42 mg*h/L. 
Discussion 
5-FU  has  been  widely  used  to  treat  metastatic 
colorectal cancer, and its efficacy is improved when 
administered  with  other  drugs.  Various  doses  of 
5-FU,  and  schedules  and  routes  of  administration 
have been applied, and there is a consensus that re-
sponse rates are improved with increased dose and 
prolonged infusion. With indwelling venous catheters 
and portable infusion pumps, patients can be treated 
on an out-patient basis. However, portable infusion 
pumps  can  still  be  inconvenient,  and  indwelling 
catheters  can  result  in  complications  including 
thrombosis and infections. Oral fluoropyrimidine is a 
promising alternative to the constant infusion of 5-FU, 
and  pharmacokinetic  studies  have  found  that  the 
consecutive  oral  administration  of  UFT  at  370 
mg/m2/day as tegafur provided a steady-state con-
centration of 5-FU comparable to that achieved by a 
5-day constant infusion at 250 mg/m2/day, and in-
jecting a bolus of 5-FU results in ultra-high concen-
trations followed by rapid dissapperance [20,21]. 
We  have  proposed  the  CPT-11  +  5-FU/LV  + 
UFT/LV chemotherapy, in which repetitive oral ad-
ministration  of  UFT/LV  replaces  the  infusion  of 
5-FU/LV in the FOLFIRI regimen [15]. In this study, 
the  effect  of  a  bolus  injection  of  5-FU  on  its 
steady-state  pharmacokinetics  was  examined  in  the 
CPT-11  +  5-FU/LV  +  UFT/LV  chemotherapy.  The 
bolus injection of 5-FU increased its plasma concen-
trations  at  24  hr  or  48  hr  3-fold  (Table  1),  and  the 
AUC0-48 values of 22.16 mg*h/L and 0.65 mg*h/L in 
the patients with and without the bolus injection, re-
spectively (Table 4).   It is noted that the dose of 5-FU 
for the first 48 hr was 889.9 mg/ m2 and 389.9 mg/m2, 
respectively, and there was no dose-linearity in the 
AUC0-48 values. Reportedly, it has been suggested that 
the toxicity and efficacy of 5-FU are correlated to 5-FU 
exposure quantified by the AUC in a steady-state, and 
the target level of 5-FU exposure to ensure a certain 
efficacy  is  in  the  range  of  24-30  mg*h/L  [22-30]. 
Therefore, the bolus injection of 5-FU was thought to 
be necessary to ensure the efficacy in the  CPT-11 + 
5-FU/LV + UFT/LV chemotherapy, and presumably 
also in the FOLFIRI and FOLFOX regimens consisting 
of both of bolus injection and continuous infusion of 
5-FU.  A  review  of  preclinical  reports  suggests  that 
short-term,  high-dose  administration  results  in 
growth inhibition refractory to thymidine protection, 
whereas long-term, low-dose exposure produces cy-
totoxicity [31]. Here, the injection of 5-FU was proved 
to alter the systemic exposure to 5-FU, which would 
contribute, in part, to the synergetic effects of the in-
jection and continuous infusion of 5-FU. 
On the other hand, critical evaluation of current 
treatment  protocols  in  colorectal  cancer  have  sug-
gested that the bolus injection of 5-FU is not always 
necessary  to  ensure  the  efficacy  [1-4].  The  LV5FU2 
regimen consisting of a bolus injection of 5-FU and 
infusion  of  5-FU/LV  resulted  in  a  median  survival 
time  (MST)  of  14.7  months  in  the  first-line  therapy 
[32,33]. The AIO regimen (the infusion of 5-FU/LV) 
provided the MST of 16.9 months [34], whereas the 
Mayo Clinic regimen (the bolus 5-FU/LV) [35] gave 
the MST of 16.1 months [1]. A bolus injection of 5-FU 
might be omitted in the FOLFIRI and FOLFOX regi-
mens  in  the  cases  that  the  appearance  of  bo-
lus-associated  significant  side  effects  would  be  ex-
pected,  although  no  information  on  the  effect  of 
omission  on  efficacy.  Consequently,  further  clinical 
investigations should be performed to clarify the ne-
cessity of a bolus injection of 5-FU.  
Interestingly, 5-FU was detected at 336 hr after 
the start of treatment, that is, at 226 hr after the last 
administration of UFT/LV in the patients with bolus 
injection of 5-FU, whereas it was not detected for no 
bolus injection (Table 1). This observation can hardly 
be explained by the pharmacokinetic profile of 5-FU, 
i.e., an apparent half-life of about 10 min [36]. An in-Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
410 
tracellular  pool  of  5-FU  might  build  up  by  a  bolus 
injection of 5-FU, and the pooled 5-FU might be re-
absorbed  into  systemic  circulation  with  very  slow 
speed for a long time. Nonclinical animal experiments 
might support this speculation. 
 
Table 1. Effect of bolus injection of 5-fluorouracil (5-FU) on the plasma concentration of 5-FU (ng/mL) in the CPT-11 
+ 5-FU/LV + UFT/LV chemotherapy 
a) 
Time (hr) 
 
5-FU dosing 
 
with bolus injection of 5-FU (N = 5)  without bolus injection of 5-FU (N = 5)  P 
0  1st oral UFT/LV  0.0±0.0  0.0±0.0  NS 
0.5    14.0±31.2  1.5±3.4  NS 
1    37.0±48.9  19.8±18.7  NS 
2    28.5±18.7  79.3±64.7  NS 
2.5  bolus injection b)  81751.0±49135.1  67.3±45.2  <0.05 
2.75    21161.2±4592.7  41.4±36.9  <0.05 
3    9326.7±2085.7  22.4±20.7  <0.05 
3.5    1845.7±1308.2  14.0±7.6  <0.05 
4    485.4±229.3  11.0±6.4  <0.05 
8  2nd oral UFT/LV  25.5±10.9  5.7±6.6  <0.05 
10    39.5±14.3  22.4±17.3  NS 
24  4th oral UFT/LV  27.4±12.0  9.4±8.0  <0.05 
48  7th oral UFT/LV  31.3±11.5  10.4±8.4  <0.05 
336    15.8±11.9  0.0±0.0  <0.05 
The values are the mean±SD. 
a) Protocol is indicated in Figure 1. “Time 0” means 9:00 on day 1, the time of the first oral administration of UFT/LV at 100 mg x 3 as 
tegafur/m2/day and 25 mg x 3/day, respectively. The intravenous infusion of CPT-11 at 100 mg/m2 was done from Time = 0.5 hr to 2 hr, 
and followed by the infusion of l-LV at 15 mg/m2 for 30 min. Immediately thereafter, a bolus of 5-FU was injected at a dose of 500 mg/m2. 
b) Five of 10 patients were not injected with a bolus of 5-FU. 
 
Table 2. Effect of bolus injection of 5-fluorouracil (5-FU) on the plasma concentration of uracil (ng/mL) in the CPT-11 
+ 5-FU/LV + UFT/LV chemotherapy 
a) 
Time (hr)  5-FU dosing  with bolus injection of 5-FU (N = 5)  without bolus injection of 5-FU (N = 5)  P 
 
0  1st oral UFT/LV  22.6±19.3  10.1±19.6  NS 
0.5    1429.6±3133.5  26.6±41.6  NS 
1    983.9±1112.2  660.2±704.4  NS 
2    381.9±277.0  2169.6±2124.2  NS 
2.5  bolus injection b)  579.6±916.7  2031.7±2070.5  NS 
2.75    287.7 (2450.3)  622.0 (4232.1)  NS 
3    325.1 (3447.7)  224.6 (944.2)  NS 
3.5    765.7±1207.9  66.7±94.0  NS 
4    137.9 (647.3)  24.2 (41.8)  <0.05 
8  2nd oral UFT/LV  53.1±9.8  22.9±29.1  NS 
10    415.6±333.2  271.6±240.5  NS 
24  4th oral UFT/LV  37.6±5.5  17.1±20.0  NS 
48  7th oral UFT/LV  30.9 (13.4)  5.0 (25.9)  NS 
336    19.8±15.5  1.4±1.9  NS 
The values are the mean±SD, when the normality assumption held, and are medians with interquartile ranges in parentheses, when failed.  
a) Protocol is indicated in Figure 1. “Time 0” means 9:00 on day 1, the time of the first oral administration of UFT/LV at 100 mg x 3 as 
tegafur/m2/day and 25 mg x 3/day, respectively. The intravenous infusion of CPT-11 at 100 mg/m2 was done from Time = 0.5 hr to 2 hr, 
and followed by the infusion of l-LV at 15 mg/m2 for 30 min. Immediately thereafter, a bolus of 5-FU was injected at a dose of 500 mg/m2. 
b) Five of 10 patients were not injected with a bolus of 5-FU. Int. J. Med. Sci. 2011, 8 
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Table 3. Effect of bolus injection of 5-fluorouracil (5-FU) on the plasma concentration of tegafur (ng/mL) in the 
CPT-11 + 5-FU/LV + UFT/LV chemotherapy 
a) 
Time (hr)  5-FU dosing  with bolus injection of 5-FU (N = 5)  without bolus injection of 5-FU (N = 5)  P 
 
 
0 
 
1st oral UFT/LV 
 
0.0±0.0 
 
0.0±0.0 
 
NS 
0.5    938.7 (4028.0)  548.1 (1243.7)  NS 
1    3456.2±2299.1  2669.5±2003.5  NS 
2    5453.3±2282.2  6394.3±2478.1  NS 
2.5  bolus injection b)  5571.8±1512.6  6770.0±1697.6  NS 
2.75    5667.8±1305.9  6600.0±1611.4  NS 
3    5498.1±1246.9  6233.5±1621.3  NS 
3.5    4783.9±1528.9  5574.5±1313.9  NS 
4    5129.5±1339.3  4897.0±1607.2  NS 
8  2nd oral UFT/LV  3556.0±1111.4  3292.4±1007.6  NS 
10    7040.0±1721.2  7093.6±2711.9  NS 
24  4th oral UFT/LV  3932.4±1042.7  3094.1±867.6  NS 
48  7th oral UFT/LV  5090.8±1794.3  4167.7±1639.4  NS 
336 
 
 
 
0.0±0.0 
 
0.0±0.0 
 
NS 
 
The values are the mean±SD, when the normality assumption held, and are medians with interquartile ranges in parentheses, when failed.  
a) Protocol is indicated in Figure 1. “Time 0” means 9:00 on day 1, the time of the first oral administration of UFT/LV at 100 mg x 3 as 
tegafur/m2/day and 25 mg x 3/day, respectively. The intravenous infusion of CPT-11 at 100 mg/m2 was done from Time = 0.5 hr to 2 hr, 
and followed by the infusion of l-LV at 15 mg/m2 for 30 min. Immediately thereafter, a bolus of 5-FU was injected at a dose of 500 mg/m2. 
b) Five of 10 patients were not injected with a bolus of 5-FU. 
 
Table 4. Area under the plasma concentration-time curve from 0 hr to 48 hr (AUC0-48) of uracil, 5-fluorouracil (5-FU) 
and tegafur in patients treated with the CPT-11 + 5-FU/LV + UFT/LV chemotherapy 
AUC0-48 (mg*h/L)  uracil  5-FU  tegafur 
 
with bolus injection of 5-FU 
 
 
8.50±3.68 
 
 
22.16±6.57 
 
 
227.83±50.91 
 
without bolus injection of 5-FU 
 
6.17±2.49 
 
0.65±0.42 * 
 
202.98±61.46 
 
The values are the mean±SD.  
* P < 0.05, compared with the data obtained with bolus injection of 5-FU.  
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